Momenta Pharmaceuticals Completes Strategic Review to Refocus its Operations and Drive Shareholder Value
October 01, 2018 06:00 ET
|
Momenta Pharmaceuticals, Inc.
-- Company to Prioritize Pipeline of Novel Drug Candidates for Immune-Mediated Diseases and Reduce Investment in Biosimilars by Focusing on Two Later-stage Assets -- -- Company to Streamline...
Momenta Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 09, 2018 06:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2018 and provided a...
Momenta Pharmaceuticals Announces Date of Second Quarter 2018 Financial Results Conference Call and Webcast
August 02, 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will release its financial results for the second quarter ended June 30,...
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 39th Annual Global Healthcare Conference
June 06, 2018 16:02 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will present at the Goldman Sachs 39th Annual Global Healthcare Conference. ...
Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity
May 17, 2018 16:05 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the upcoming presentation describing the broad potential for anti-FcRn therapeutics and...
Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018
May 10, 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 08, 2018 07:01 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2018 and provided a...
Momenta Pharmaceuticals Announces Date of First Quarter 2018 Financial Results Conference Call and Webcast
May 01, 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will release its financial results for the first quarter ended March 31, 2018...
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
March 05, 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
February 21, 2018 08:00 ET
|
Momenta Pharmaceuticals, Inc.
--Ended 2017 with a healthy cash position of $380M -- --Recently announced FDA approval and launch of Glatopa® 40 mg-- CAMBRIDGE, Mass., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Momenta...